title: Salvage treatment of histoplasmosis with posaconazole.
abstract: Six patients received salvage treatment with posaconazole oral suspension (800 mg/day in divided doses) for severe forms of histoplasmosis. One patient had pulmonary disease and 5 had disseminated disease. Previous antifungal therapy consisted of amphotericin B, itraconazole, fluconazole, or voriconazole. Posaconazole treatment duration for individual patients ranged from 6 weeks to 34 weeks. All patients had successful clinical outcomes with significant clinical improvements noted during the first month of therapy. Although the number of patients evaluated in this case series is small, the findings are encouraging and provide preliminary evidence that posaconazole may be a useful salvage treatment option for histoplasmosis involving a variety of infected tissues and organs.
authors.affiliation: Corporación para Investigaciones Biológicas, Carrera, Medellín, Colombia. angelares@geo.net.co <angelares@geo.net.co>
authors.forename: Angela
authors.initials: A
authors.lastname: Restrepo
authors.forename: Angela
authors.initials: A
authors.lastname: Tobón
authors.forename: Benjamin
authors.initials: B
authors.lastname: Clark
authors.forename: Donald R
authors.initials: DR
authors.lastname: Graham
authors.forename: Gavin
authors.initials: G
authors.lastname: Corcoran
authors.forename: Robert W
authors.initials: RW
authors.lastname: Bradsher
authors.forename: Mitchell
authors.initials: M
authors.lastname: Goldman
authors.forename: George
authors.initials: G
authors.lastname: Pankey
authors.forename: Thomas
authors.initials: T
authors.lastname: Moore
authors.forename: Ricardo
authors.initials: R
authors.lastname: Negroni
authors.forename: John R
authors.initials: JR
authors.lastname: Graybill
mesh_terms: D000293:Adolescent; D000328:Adult; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002555:Cerebrospinal Fluid / Q000382:microbiology; D015521:Ethmoid Sinusitis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D006658:Histoplasma / Q000187:drug effects* / Q000302:isolation & purification; D006660:Histoplasmosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy / Q000382:microbiology; D016921:Meningitis, Fungal / Q000188:drug therapy / Q000382:microbiology; D008875:Middle Aged; D016879:Salvage Therapy; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole